Skip to Main Content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

The Faculty of Medicine - Immunology and Cancer Research: Mandelboim Ofer


Last updated December 2021 -  Immunology and Cancer Research

List of Publications

(1) Seidel E, Dassa L, Kahlon S, Tirosh B, Halenius A, Seidel Malkinson T, et al. A slowly cleaved viral signal peptide acts as a protein-integral immune evasion domain. Nat Commun 2021;12(1).

(2) Chaouat AE, Seliger B, Mandelboim O, Schmiedel D. The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition. Front Immunol 2021;12.

(3) Bauer M, Jasinski-Bergner S, Mandelboim O, Wickenhauser C, Seliger B. Epstein–barr virus—associated malignancies and immune escape: The role of the tumor microenvironment and tumor cell evasion strategies. Cancers 2021;13(20).

(4) Isaacson B, Baron M, Yamin R, Bachrach G, Levi-Schaffer F, Granot Z, et al. The inhibitory receptor CD300a is essential for neutrophil-mediated clearance of urinary tract infection in mice. Eur J Immunol 2021;51(9):2218-2224.

(5) Shhadeh A, Galaski J, Alon-Maimon T, Fahoum J, Wiener R, Slade DJ, et al. CEACAM1 Activation by CbpF-Expressing E. coli. Front Cell Infect Microbiol 2021;11.

(6) Galaski J, Shhadeh A, Umaña A, Yoo CC, Arpinati L, Isaacson B, et al. Fusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation. Front Cell Infect Microbiol 2021;11.

(7) Elias S, Kol I, Kahlon S, Amore R, Zeibak M, Mevorach D, et al. Anti-RhD antibody therapy modulates human natural killer cell function. Haematologica 2021;106(7):1846-1856.

(8) Seidel E, Dassa L, Schuler C, Oiknine-Djian E, Wolf DG, Le-Trilling VTK, et al. The human cytomegalovirus protein UL147A downregulates the most prevalent MICA allele: MICA*008, to evade NK cell-mediated killing. PLoS Pathog 2021;17(5).

(9) Chaushu S, Klein Y, Mandelboim O, Barenholz Y, Fleissig O. Immune Changes Induced by Orthodontic Forces: A Critical Review. J Dent Res 2021.

(10) Duev-Cohen A, Isaacson B, Berhani O, Charpak-Amikam Y, Friedman N, Drori Y, et al. Altered nkp46 recognition and elimination of influenza b viruses. Viruses 2021;13(1).

(11) Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun 2020;11(1).

(12) Klein Y, Fleissig O, Polak D, Barenholz Y, Mandelboim O, Chaushu S. Immunorthodontics: in vivo gene expression of orthodontic tooth movement. Sci Rep 2020;10(1).

(13) Abed J, Maalouf N, Manson AL, Earl AM, Parhi L, Emgård JEM, et al. Colon Cancer-Associated Fusobacterium nucleatum May Originate From the Oral Cavity and Reach Colon Tumors via the Circulatory System. Front Cell Infect Microbiol 2020;10.

(14) Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, et al. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharmacol Res 2020;158.

(15) Jasinski-Bergner S, Mandelboim O, Seliger B. Molecular mechanisms of human herpes viruses inferring with host immune surveillance. J Immunother Cancer 2020;8(2).

(16) Diab M, Schmiedel D, Seidel E, Bacharach E, Mandelboim O. Human metapneumovirus escapes NK cell recognition through the downregulation of stress-induced ligands for NKG2D. Viruses 2020;12(7).

(17) Reches A, Ophir Y, Stein N, Kol I, Isaacson B, Charpak Amikam Y, et al. Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity. J Immunother Cancer 2020;8(1).

(18) Reches A, Berhani O, Mandelboim O. A unique regulation region in the 3′ UTR of HLA-G with a promising potential. Int J Mol Sci 2020;21(3).

(19) Finkel Y, Schmiedel D, Tai-Schmiedel J, Nachshon A, Winkler R, Dobesova M, et al. Comprehensive annotations of human herpesvirus 6A and 6B genomes reveal novel and conserved genomic features. eLife 2020;9.

(20) Geljic IS, Brlic PK, Angulo G, Brizic I, Lisnic B, Jenus T, et al. Cytomegalovirus protein m154 perturbs the adaptor protein-1 compartment mediating broad-spectrum immune evasion. eLife 2020;9.

(21) Obiedat A, Charpak-Amikam Y, Tai-Schmiedel J, Seidel E, Mahameed M, Avril T, et al. The integrated stress response promotes B7H6 expression. J Mol Med 2020;98(1):135-148.

(22) Isaacson B, Mandelboim O. Natural killer cells control metastasis via structural editing of primary tumors in mice. Cancer Immunol Immunother 2019;68(10):1721-1724.

(23) Friedrich M, Jasinski-Bergner S, Lazaridou M-, Subbarayan K, Massa C, Tretbar S, et al. Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy. Cancer Immunol Immunother 2019;68(10):1689-1700.

(24) Goldman-Wohl D, Gamliel M, Mandelboim O, Yagel S. Learning from experience: cellular and molecular bases for improved outcome in subsequent pregnancies. Am J Obstet Gynecol 2019;221(3):183-193.

(25) Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. OncoImmunology 2019;8(6).

(26) Gur C, Maalouf N, Gerhard M, Singer BB, Emgård J, Temper V, et al. The Helicobacter pylori HopQ outermembrane protein inhibits immune cell activities. OncoImmunology 2019;8(4).

(27) Obiedat A, Seidel E, Mahameed M, Bernani O, Tsukerman P, Voutetakis K, et al. Transcription of the NKG2D ligand MICA is suppressed by the IRE1/XBP1 pathway of the unfolded protein response through the regulation of E2F1. FASEB J 2019;33(3):3481-3495.

(28) Berhani O, Glasner A, Kahlon S, Duev-Cohen A, Yamin R, Horwitz E, et al. Human anti-NKp46 antibody for studies of NKp46-dependent NK cell function and its applications for type 1 diabetes and cancer research. Eur J Immunol 2019;49(2):228-241.

(29) Stein N, Berhani O, Schmiedel D, Duev-Cohen A, Seidel E, Kol I, et al. IFNG-AS1 Enhances Interferon Gamma Production in Human Natural Killer Cells. iScience 2019;11:466-473.

(30) Elias S, Kahlon S, Duev-Cohen A, Mandelboim O. A BW reporter system for studying receptor-ligand interactions. J Visualized Exp 2019;2019(143).

(31) Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 2019;16(1):51-63.

(32) Rätsep MT, Moore SD, Jafri S, Mitchell M, Brady HJM, Mandelboim O, et al. Spontaneous pulmonary hypertension in genetic mouse models of natural killer cell deficiency. Am J Physiol Lung Cell Mol Physiol 2018;315(6):L977-L990.

(33) Schmiedel D, Mandelboim O. NKG2D ligands-critical targets for cancer immune escape and therapy. Front Immunol 2018;9(SEP).

(34) Dassa L, Seidel E, Oiknine-Djian E, Yamin R, Wolf DG, Le-Trilling VTK, et al. The human cytomegalovirus protein UL148A downregulates the NK cell-activating ligand MICA to avoid NK cell attack. J Virol 2018;92(17).

(35) Isaacson B, Mandelboim O. Sweet Killers: NK Cells Need Glycolysis to Kill Tumors. Cell Metab 2018;28(2):183-184.

(36) Edri A, Shemesh A, Iraqi M, Matalon O, Brusilovsky M, Hadad U, et al. The Ebola-Glycoprotein modulates the function of Natural killer cells. Front Immunol 2018;9(JUL).

(37) Elias S, Kahlon S, Kotzur R, Kaynan N, Mandelboim O. Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL). OncoImmunology 2018;7(6).

(38) Gamliel M, Goldman-Wohl D, Isaacson B, Gur C, Stein N, Yamin R, et al. Trained Memory of Human Uterine NK Cells Enhances Their Function in Subsequent Pregnancies. Immunity 2018;48(5):951-962.e5.

(39) Toledano T, Vitenshtein A, Stern-Ginossar N, Seidel E, Mandelboim O. Decay of the stress-induced ligand MICA is controlled by the expression of an alternative 39 untranslated region. J Immunol 2018;200(8):2819-2825.

(40) Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, et al. Erratum: NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis (Immunity (2018) 48(1) (107–119.e4)(S1074761317305368)(10.1016/j.immuni.2017.12.007)). Immunity 2018;48(2):396-398.

(41) Levi-Schaffer F, Mandelboim O. Inhibitory and Coactivating Receptors Recognising the Same Ligand: Immune Homeostasis Exploited by Pathogens and Tumours. Trends Immunol 2018;39(2):112-122.

(42) Glasner A, Levi A, Enk J, Isaacson B, Viukov S, Orlanski S, et al. NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity 2018;48(1):107-119.e4.

(43) Glasner A, Isaacson B, Viukov S, Neuman T, Friedman N, Mandelboim M, et al. Increased NK cell immunity in a transgenic mouse model of NKp46 overexpression. Sci Rep 2017;7(1).

(44) Charpak-Amikam Y, Kubsch T, Seidel E, Oiknine-Djian E, Cavaletto N, Yamin R, et al. Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Sci Rep 2017;7(1).

(45) Glasner A, Oiknine-Djian E, Weisblum Y, Diab M, Panet A, Wolf DG, et al. Zika virus escapes NK cell detection by upregulating major histocompatibility complex class I molecules. J Virol 2017;91(22).

(46) Bar-On Y, Charpak-Amikam Y, Glasner A, Isaacson B, Duev-Cohen A, Tsukerman P, et al. NKp46 recognizes the sigma1 protein of reovirus: Implications for reovirus-based cancer therapy. J Virol 2017;91(19).

(47) Eichmüller SB, Osen W, Mandelboim O, Seliger B. Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape. J Natl Cancer Inst 2017;109(10).

(48) Miletic A, Lenartic M, Popovic B, Brizic I, Trsan T, Miklic K, et al. NCR1-deficiency diminishes the generation of protective murine cytomegalovirus antibodies by limiting follicular helper T-cell maturation. Eur J Immunol 2017;47(9):1443-1456.

(49) Isaacson B, Hadad T, Glasner A, Gur C, Granot Z, Bachrach G, et al. Stromal Cell-Derived Factor 1 Mediates Immune Cell Attraction upon Urinary Tract Infection. Cell Rep 2017;20(1):40-47.

(50) Abed J, Maalouf N, Parhi L, Chaushu S, Mandelboim O, Bachrach G. Tumor targeting by Fusobacterium nucleatum: A Pilot Study and future Perspectives. Front Cell Infect Microbiol 2017;7(JUN).

(51) Berhani O, Nachmani D, Yamin R, Schmiedel D, Bar-On Y, Mandelboim O. Vigilin regulates the expression of the stress-induced ligand MICB by Interacting with Its 5′ Untranslated Region. J Immunol 2017;198(9):3662-3670.

(52) Stein N, Tsukerman P, Mandelboim O. The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Hum Antibodies 2017;25(3-4):111-119.

(53) Schmiedel D, Mandelboim O. Disarming cellular alarm systems-manipulation of stress-induced NKG2D ligands by human herpesviruses. Front Immunol 2017;8(APR).

(54) Diab M, Glasner A, Isaacson B, Bar-On Y, Drori Y, Yamin R, et al. NK-cell receptors NKp46 and NCR1 control human metapneumovirus infection. Eur J Immunol 2017;47(4):692-703.

(55) Glasner A, Isaacson B, Mandelboim O. Expression and function of NKp46 W32R: The human homologous protein of mouse NKp46 W32R (Noé). Sci Rep 2017;7.

(56) Enk J, Levi A, Weisblum Y, Yamin R, Charpak-Amikam Y, Wolf DG, et al. HSV1 MicroRNA Modulation of GPI Anchoring and Downstream Immune Evasion. Cell Rep 2016;17(4):949-956.

(57) Vitenshtein A, Charpak-Amikam Y, Yamin R, Bauman Y, Isaacson B, Stein N, et al. NK Cell Recognition of Candida glabrata through Binding of NKp46 and NCR1 to Fungal Ligands Epa1, Epa6, and Epa7. Cell Host and Microbe 2016;20(4):527-534.

(58) Rovis TL, Brlic PK, Kaynan N, Lisnic VJ, Brizic I, Jordan S, et al. Inflammatory monocytes and NK cells play a crucial role in DNAM-1-dependent control of cytomegalovirus infection. J Exp Med 2016;213(9):1835-1850.

(59) Ophir Y, Duev-Cohen A, Yamin R, Tsukerman P, Bauman Y, Gamliel M, et al. PILRα binds an unknown receptor expressed primarily on CD56bright and decidual-NK cells and activates NK cell functions. Oncotarget 2016;7(27):40953-40964.

(60) Baía D, Pou J, Jones D, Mandelboim O, Trowsdale J, Muntasell A, et al. Interaction of the LILRB1 inhibitory receptor with HLA class Ia dimers. Eur J Immunol 2016;46(7):1681-1690.

(61) Reches A, Nachmani D, Berhani O, Duev-Cohen A, Shreibman D, Ophir Y, et al. HNRNPR regulates the expression of classical and Nonclassical MHC Class i Proteins. J Immunol 2016;196(12):4967-4976.

(62) Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, et al. CEACAM1-Mediated Inhibition of Virus Production. Cell Rep 2016;15(11):2331-2339.

(63) Yamin R, Lecker LSM, Weisblum Y, Vitenshtein A, Le-Trilling VTK, Wolf DG, et al. HCMV vCXCL1 Binds Several Chemokine Receptors and Preferentially Attracts Neutrophils over NK Cells by Interacting with CXCR2. Cell Rep 2016;15(7):1542-1553.

(64) Jasinski-Bergner S, Reches A, Stoehr C, Massa C, Gonschorek E, Huettelmaier S, et al. Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma. Oncotarget 2016;7(18):26866-26878.

(65) Houston A, Williams JM, Rovis TL, Shanley DK, O’Riordan RT, Kiely PA, et al. Pregnancy-specific glycoprotein expression in normal gastrointestinal tract and in tumors detected with novel monoclonal antibodies. mAbs 2016;8(3):491-500.

(66) Bauman Y, Drayman N, Ben-Nun-Shaul O, Vitenstein A, Yamin R, Ophir Y, et al. Downregulation of the stress-induced ligand ULBP1 following SV40 infection confers viral evasion from NK cell cytotoxicity. Oncotarget 2016;7(13):15369-15381.

(67) Schmiedel D, Tai J, Yamin R, Berhani O, Bauman Y, Mandelboim O. The RNA binding protein imp3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB. eLife 2016;5(MARCH2016).

(68) Duev-Cohen A, Bar-On Y, Glasner A, Berhani O, Ophir Y, Levi-Schaffer F, et al. The human 2B4 and NTB-A receptors bind the influenza viral hemagglutinin and co-stimulate NK cell cytotoxicity. Oncotarget 2016;7(11):13093-13105.

(69) Schmiedel D, Tai J, Levi-Schaffer F, Dovrat S, Mandelboim O. Human herpesvirus 6B downregulates expression of activating ligands during lytic infection to escape elimination by natural killer cells. J Virol 2016;90(21):9608-9617.

(70) Diab M, Vitenshtein A, Drori Y, Yamin R, Danziger O, Zamostiano R, et al. Suppression of human metapneumovirus (HMPV) infection by the innate sensing gene CEACAM1. Oncotarget 2016;7(41):66468-66479.

(71) Glasner A, Roth Z, Varvak A, Miletic A, Isaacson B, Bar-On Y, et al. Identification of putative novel O-glycosylations in the NK killer receptor Ncr1 essential for its activity. Cell Discov 2015;1.

(72) Okada K, Sato S, Sato A, Mandelboim O, Yamasoba T, Kiyono H. Identification and analysis of natural killer cells in murine nasal passages. PLoS ONE 2015;10(11).

(73) Weisblum Y, Panet A, Zakay-Rones Z, Vitenshtein A, Haimov-Kochman R, Goldman-Wohl D, et al. Human cytomegalovirus induces a distinct innate immune response in the maternal-fetal interface. Virology 2015;485:289-296.

(74) Glasner A, Simic H, Miklić K, Roth Z, Berhani O, Khalaila I, et al. Expression, function, and molecular properties of the killer receptor Ncr1-Noé. J Immunol 2015;195(8):3959-3969.

(75) Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, et al. Correction: Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS ONE 2015;10(5).

(76) Brusilovsky M, Radinsky O, Cohen L, Yossef R, Shemesh A, Braiman A, et al. Regulation of natural cytotoxicity receptors by heparan sulfate proteoglycans in -cis: A lesson from NKp44. Eur J Immunol 2015;45(4):1180-1191.

(77) Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, Arnon TI, et al. Erratum: Novel APC-like properties of human NK cells directly regulate T cell activation (Journal of Clinical Investigation (2015) 125:4 (1763)). J Clin Invest 2015;125(4):1763.

(78) Wensveen FM, Jelenčić V, Valentić S, Šestan M, Wensveen TT, Theurich S, et al. NK cells link obesity-induced adipose stress to inflammation and insulin resistance. Nat Immunol 2015;16(4):376-385.

(79) Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Erratum: Novel insights on human NK cells' immunological modalities revealed by gene expression profiling (J Immunol (2015) 173 (6547-6563)). J Immunol 2015;194(5):2447-2448.

(80) Yossef R, Gur C, Shemesh A, Guttman O, Hadad U, Nedvetzki S, et al. Targeting natural killer cell reactivity by employing antibody to Nkp46: Implications for type 1 diabetes. PLoS ONE 2015;10(2).

(81) Seidel E, Le VTK, Bar-On Y, Tsukerman P, Enk J, Yamin R, et al. Dynamic Co-evolution of Host and Pathogen: HCMV Downregulates the Prevalent Allele MICA*008 to Escape Elimination by NK Cells. Cell Rep 2015;10(6):968-982.

(82) Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, et al. Binding of the Fap2 protein of fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015;42(2):344-355.

(83) Tsukerman P, Eisenstein EM, Chavkin M, Schmiedel D, Wong E, Werner M, et al. Cytokine secretion and NK cell activity in human ADAM17 deficiency. Oncotarget 2015;6(42):44151-44160.

(84) Gur C, Mandelboim O, Bachrach G. “Messieurs, c’est les microbes qui auront le dernier mot”: Gentlemen, it is the microbes who have the last word (Louis Pasteur)—Fusobacterium nucleatum protect tumors from killing by immune cells. OncoImmunology 2015;4(9):1-3.

(85) Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, et al. Characterization of tumor infiltrating Natural Killer cell subset. Oncotarget 2015;6(15):1-9.

(86) Gotthardt D, Prchal-Murphy M, Seillet C, Glasner A, Mandelboim O, Carotta S, et al. NK cell development in bone marrow and liver: Site matters. Genes Immun 2014;15(8):584-587.

(87) Goldberger T, Mandelboim O. The use of microRNA by human viruses: Lessons from NK cells and HCMV infection. Semin Immunopathol 2014;36(6):659-674.

(88) Goldberger T, Mandelboim O. Editorial introduction for Seminars in Immunopathology special issue on “Immune modulation, properties and models of CMV”. Semin Immunopathol 2014;36(6):611-613.

(89) Jasinski-Bergner S, Mandelboim O, Seliger B. The Role of MicroRNAs in the control of innate immune response in cancer. J Natl Cancer Inst 2014;106(10).

(90) Bar-On Y, Seidel E, Tsukerman P, Mandelboim M, Mandelboim O. Influenza virus uses its neuraminidase protein to evade the recognition of two activating NK cell receptors. J Infect Dis 2014;210(3):410-418.

(91) Ghadially H, Ohana M, Elboim M, Gazit R, Gur C, Nagler A, et al. NK Cell Receptor NKp46 Regulates Graft-versus-Host Disease. Cell Rep 2014;7(6):1809-1814.

(92) Nachmani D, Gutschner T, Reches A, Diederichs S, Mandelboim O. RNA-binding proteins regulate the expression of the immune activating ligand MICB. Nat Commun 2014;5.

(93) Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood 2014;123(10):1535-1543.

(94) Tsukerman P, Yamin R, Seidel E, Khawaled S, Schmiedel D, Bar-Mag T, et al. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget 2014;5(23):12141-12150.

(95) Tsukerman P, Stern-Ginossar N, Yamin R, Ophir Y, Stanietsky AMN, Mandelboim O. Expansion of CD16 positive and negative human NK cells in response to tumor stimulation. Eur J Immunol 2014;44(5):1517-1525.

(96) Enk J, Mandelboim O. The role of natural cytotoxicity receptors in various pathologies: Emphasis on Type I diabetes. Front Immunol 2014;5(JAN).

(97) Nachmani D, Zimmermann A, Oiknine Djian E, Weisblum Y, Livneh Y, Khanh Le VT, et al. MicroRNA Editing Facilitates Immune Elimination of HCMV Infected Cells. PLoS Pathog 2014;10(2).

(98) Gur C, Coppenhagen-Glazer S, Rosenberg S, Yamin R, Enk J, Glasner A, et al. Natural killer cell-mediated host defense against uropathogenic E. coli is counteracted by bacterial hemolysinA-dependent killing of NK cells. Cell Host and Microbe 2013;14(6):664-674.

(99) Ghadially H, Horani A, Glasner A, Elboim M, Gazit R, Shoseyov D, et al. NKp46 regulates allergic responses. Eur J Immunol 2013;43(11):3006-3016.

(100) Hosomi S, Chen Z, Baker K, Chen L, Huang Y-, Olszak T, et al. CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling. Eur J Immunol 2013;43(9):2473-2483.

(101) Gur C, Enk J, Weitman E, Bachar E, Suissa Y, Cohen G, et al. The Expression of the Beta Cell-Derived Autoimmune Ligand for the Killer Receptor Nkp46 Is Attenuated in Type 2 Diabetes. PLoS ONE 2013;8(8).

(102) Yamin R, Kaynan NS, Glasner A, Vitenshtein A, Tsukerman P, Bauman Y, et al. The Viral KSHV Chemokine vMIP-II Inhibits the Migration of Naive and Activated Human NK Cells by Antagonizing Two Distinct Chemokine Receptors. PLoS Pathog 2013;9(8).

(103) Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, et al. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol 2013;43(8):2138-2150.

(104) Lankry D, Rovis TL, Jonjic S, Mandelboim O. The interaction between CD300a and phosphatidylserine inhibits tumor cell killing by NK cells. Eur J Immunol 2013;43(8):2151-2161.

(105) Bar-On Y, Glasner A, Meningher T, Achdout H, Gur C, Lankry D, et al. Neuraminidase-Mediated, NKp46-Dependent Immune-Evasion Mechanism of Influenza Viruses. Cell Rep 2013;3(4):1044-1050.

(106) Elboim M, Grodzovski I, Djian E, Wolf DG, Mandelboim O. HSV-2 Specifically Down Regulates HLA-C Expression to Render HSV-2-Infected DCs Susceptible to NK Cell Killing. PLoS Pathog 2013;9(3).

(107) Koch J, Steinle A, Watzl C, Mandelboim O. Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 2013;34(4):182-191.

(108) Sela HY, Goldman-Wohl DS, Haimov-Kochman R, Greenfield C, Natanson-Yaron S, Hamani Y, et al. Human trophectoderm apposition is regulated by interferon γ-induced protein 10 (IP-10) during early implantation. Placenta 2013;34(3):222-230.

(109) Tallerico R, Todaro M, Di Franco S, MacCalli C, Garofalo C, Sottile R, et al. Human NK cells selective targeting of colon cancer-initiating cells: A role for natural cytotoxicity receptors and MHC class i molecules. J Immunol 2013;190(5):2381-2390.

(110) Corrales-Aguilar E, Trilling M, Reinhard H, Mercé-Maldonado E, Widera M, Schaal H, et al. A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods 2013;387(1-2):21-35.

(111) Tsukerman P, Enk J, Mandelboim O. Metastamir-mediated immune evasion: MiR-10b downregulates the stress-induced molecule MICB, hence avoid recognition by NKG2D receptor. OncoImmunology 2013;2(1).

(112) Alvarez-Breckenridge CA, Yu J, Price R, Wojton J, Pradarelli J, Mao H, et al. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors. Nat Med 2012;18(12):1827-1834.

(113) Seidel E, Glasner A, Mandelboim O. Virus-mediated inhibition of natural cytotoxicity receptor recognition. Cell Mol Life Sci 2012;69(23):3911-3920.

(114) Gruda R, Brown ACN, Grabovsky V, Mizrahi S, Gur C, Feigelson SW, et al. Loss of kindlin-3 alters the threshold for NK cell activation in human leukocyte adhesion deficiency-III. Blood 2012;120(19):3915-3924.

(115) Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, et al. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012;72(21):5463-5472.

(116) Gur C, Doron S, Kfir-Erenfeld S, Horwitz E, Abu-tair L, Safadi R, et al. NKp46-mediated killing of human and mouse hepatic stellate cells attenuates liver fibrosis. Gut 2012;61(6):885-893.

(117) Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, et al. MiRNA-mediated control of HLA-G expression and function. PLoS ONE 2012;7(3).

(118) Glasner A, Ghadially H, Gur C, Stanietsky N, Tsukerman P, Enk J, et al. Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J Immunol 2012;188(6):2509-2515.

(119) Chaushu S, Wilensky A, Gur C, Shapira L, Elboim M, Halftek G, et al. Direct recognition of fusobacterium nucleatum by the NK cell natural cytotoxicity receptor NKp46 aggravates periodontal disease. PLoS Pathog 2012;8(3).

(120) Ghadially H, Keynan Y, Kimani J, Kimani M, Ball TB, Plummer FA, et al. Altered dendritic cell-natural killer interaction in Kenyan sex workers resistant to HIV-1 infection. AIDS 2012;26(4):429-436.

(121) Glasner A, Zurunic A, Meningher T, Lenac Rovis T, Tsukerman P, Bar-On Y, et al. Elucidating the mechanisms of influenza virus recognition by Ncr1. PLoS ONE 2012;7(5).

(122) Elias S, Mandelboim O. Battle of the midgets: Innate microRNA networking. RNA Biology 2012;9(6):792-798.

(123) Chen Z, Chen L, Baker K, Olszak T, Zeissig S, Huang Y-, et al. CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells. J Exp Med 2011;208(13):2633-2640.

(124) Gur C, Enk J, Kassem SA, Suissa Y, Magenheim J, Stolovich-Rain M, et al. Recognition and killing of human and murine pancreatic β cells by the NK receptor NKp46. J Immunol 2011;187(6):3096-3103.

(125) Elhaik-Goldman S, Kafka D, Yossef R, Hadad U, Elkabets M, Vallon-Eberhard A, et al. The natural cytotoxicity receptor 1 contribution to early clearance of Streptococcus pneumoniae and to natural killer-macrophage cross talk. PLoS ONE 2011;6(8).

(126) Nachmani D, Mandelboim O. Human cytomegalovirus miRNAs. Future Virol 2011;6(8):909-916.

(127) Bauman Y, Nachmani D, Vitenshtein A, Tsukerman P, Drayman N, Stern-Ginossar N, et al. An identical miRNA of the human JC and BK polyoma viruses targets the stress-induced ligand ULBP3 to escape immune elimination. Cell Host and Microbe 2011;9(2):93-102.

(128) Bauman Y, Mandelboim O. MicroRNA based immunoevasion mechanism of human polyomaviruses. RNA Biology 2011;8(4).

(129) Stanietsky N, Mandelboim O. Paired NK cell receptors controlling NK cytotoxicity. FEBS Lett 2010;584(24):4895-4900.

(130) Stern-Ginossar N, Mandelboim O. Receptors on NK cells. Natural Killer Cells; 2010. p. 155-168.

(131) Lankry D, Simic H, Klieger Y, Levi-Schaffer F, Jonjic S, Mandelboim O. Expression and function of CD300 in NK cells. J Immunol 2010;185(5):2877-2886.

(132) Nachmani D, Lankry D, Wolf DG, Mandelboim O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol 2010;11(9):806-813.

(133) Manaster I, Mandelboim O. The Unique Properties of Uterine NK Cells. Am J Reprod Immunol 2010;63(6):434-444.

(134) Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010;184(10):5637-5644.

(135) Mendelson M, Tekoah Y, Zilka A, Gershoni-Yahalom O, Gazit R, Achdout H, et al. NKp46 O-glycan sequences that are involved in the interaction with hemagglutinin type 1 of influenza virus. J Virol 2010;84(8):3789-3797.

(136) Achdout H, Meningher T, Hirsh S, Glasner A, Bar-On Y, Gur C, et al. Killing of avian and swine influenza virus by natural killer cells. J Virol 2010;84(8):3993-4001.

(137) Betser-Cohen G, Mizrahi S, Elboim M, Alsheich-Bartok O, Mandelboim O. The association of MHC class I proteins with the 2B4 receptor inhibits self-killing of human NK cells. J Immunol 2010;184(6):2761-2768.

(138) Gur C, Porgador A, Elboim M, Gazit R, Mizrahi S, Stern-Ginossar N, et al. The activating receptor NKp46 is essential for the development of type 1 diabetes. Nat Immunol 2010;11(2):121-128.

(139) Gonen-Gross T, Goldman-Wohl D, Huppertz B, Lankry D, Greenfield C, Natanson-Yaron S, et al. Inhibitory NK receptor recognition of HLA-G: Regulation by contact residues and by cell specific expression at the fetal-maternal interface. PLoS ONE 2010;5(1).

(140) Lankry D, Gazit R, Mandelboim O. Methods to identify and characterize different NK cell receptors and their ligands. Methods Mol Biol 2010;612:249-273.

(141) Manaster I, Gazit R, Goldman-Wohl D, Stern-Ginossar N, Mizrahi S, Yagel S, et al. Notch activation enhances IFNγ secretion by human peripheral blood and decidual NK cells. J Reprod Immunol 2010;84(1):1-7.

(142) Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VSG, Mandelboim O, Renauld J-, et al. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol 2009;183(10):6579-6587.

(143) Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 2009;106(42):17858-17863.

(144) Stern-Ginossar N, Saleh N, Goldberg MD, Prichard M, Wolf DG, Mandelboim O. Analysis of human cytomegalovirus-encoded microRNA activity during infection. J Virol 2009;83(20):10684-10693.

(145) Stern-Ginossar N, Mandelboim O. An integrated view of the regulation of NKG2D ligands. Immunology 2009;128(1):1-6.

(146) Nachmani D, Stern-Ginossar N, Sarid R, Mandelboim O. Diverse Herpesvirus MicroRNAs Target the Stress-Induced Immune Ligand MICB to Escape Recognition by Natural Killer Cells. Cell Host and Microbe 2009;5(4):376-385.

(147) Halfteck GG, Elboim M, Gur C, Achdout H, Ghadially H, Mandelboim O. Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1. J Immunol 2009;182(4):2221-2230.

(148) Beuneu H, Deguine J, Breart B, Mandelboim O, Di Santo JP, Bousso P. Dynamic behavior of NK cells during activation in lymph nodes. Blood 2009;114(15):3227-3234.

(149) Satoh-Takayama N, Vosshenrich CAJ, Lesjean-Pottier S, Sawa S, Lochner M, Rattis F, et al. Microbial Flora Drives Interleukin 22 Production in Intestinal NKp46+ Cells that Provide Innate Mucosal Immune Defense. Immunity 2008;29(6):958-970.

(150) Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, et al. Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 2008;9(9):1065-1073.

(151) Manaster I, Mizrahi S, Goldman-Wohl D, Sela HY, Stern-Ginossar N, Lankry D, et al. Endometrial NK cells are special immature cells that await pregnancy. J Immunol 2008;181(3):1869-1876.

(152) Achdout H, Manaster I, Mandelboim O. Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins. J Virol 2008;82(16):8030-8037.

(153) Gazit R, Hershko K, Ingbar A, Schlesinger M, Israel S, Brautbar C, et al. Immunological assessment of familial tinea corporis. J Eur Acad Dermatol Venereol 2008;22(7):871-874.

(154) Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, et al. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS ONE 2008;3(5).

(155) Manaster I, Mandelboim O. The Unique Properties of Human NK Cells in the Uterine Mucosa. Placenta 2008;29(SUPPL.):60-66.

(156) Ho JW, Hershkovitz O, Peiris M, Zilka A, Bar-Ilan A, Nal B, et al. H5-type influenza virus hemagglutinin is functionally recognized by the natural killer-activating receptor NKp44. J Virol 2008;82(4):2028-2032.

(157) Cagnano E, Hershkovitz O, Zilka A, Bar-Ilan A, Golder A, Sion-Vardy N, et al. Expression of ligands to NKp46 in benign and malignant melanocytes. J Invest Dermatol 2008;128(4):972-979.

(158) Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, Jivov S, et al. Altered glycosylation of recombinant NKp30 hampers binding to heparan sulfate: A lesson for the use of recombinant immunoreceptors as an immunological tool. Glycobiology 2008;18(1):28-41.

(159) Nachmias B, Mizrahi S, Elmalech M, Lazar I, Ashhab Y, Gazit R, et al. Manipulation of NK cytotoxicity by the IAP family member Livin. Eur J Immunol 2007;37(12):3467-3476.

(160) Yutkin V, Pode D, Pikarsky E, Mandelboim O. The Expression Level of Ligands for Natural Killer Cell Receptors Predicts Response to Bacillus Calmette-Guerin Therapy: A Pilot Study. J Urol 2007;178(6):2660-2664.

(161) Mizrahi S, Yefenof E, Gross M, Attal P, Yaakov AB, Goldman-Wohl D, et al. A phenotypic and functional characterization of NK cells in adenoids. J Leukocyte Biol 2007;82(5):1095-1105.

(162) Vosshenrich CAJ, Lesjean-Pottier S, Hasan M, Richard-Le Goff O, Corcuff E, Mandelboim O, et al. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 2007;204(11):2569-2578.

(163) Stern-Ginossar N, Nedvetzki S, Markel G, Gazit R, Betser-Cohen G, Achdout H, et al. Intercellular transfer of carcinoembryonic antigen from tumor cells to NK cells. J Immunol 2007;179(7):4424-4434.

(164) Gruda R, Achdout H, Stern-Ginossar N, Gazit R, Betser-Cohen G, Manaster I, et al. Intracellular cysteine residues in the tail of MHC class I proteins are crucial for extracellular recognition by leukocyte Ig-like receptor. J Immunol 2007;179(6):3655-3661.

(165) Mizrahi S, Markel G, Porgador A, Bushkin Y, Mandelboim O. CD100 on NK cells enhance IFNγ secretion and killing of target cells expressing CD72. PLoS ONE 2007;2(9).

(166) Lee HSW, Boulton IC, Reddin K, Wong H, Halliwell D, Mandelboim O, et al. Neisserial outer membrane vesicles bind the coinhibitory receptor carcinoembryonic antigen-related cellular adhesion molecule 1 and suppress CD4+ T lymphocyte function. Infect Immun 2007;75(9):4449-4455.

(167) Stern-Ginossar N, Elefant N, Zimmermann A, Wolf DG, Saleh N, Biton M, et al. Host immune system gene targeting by a viral miRNA. Science 2007;317(5836):376-381.

(168) Nachmias B, Lazar I, Elmalech M, Abed-El-Rahaman I, Asshab Y, Mandelboim O, et al. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin. Apoptosis 2007;12(7):1129-1142.

(169) Gazit R, Aker M, Elboim M, Achdout H, Katz G, Wolf DG, et al. NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome. Blood 2007;109(10):4306-4312.

(170) Hanna J, Mandelboim O. When killers become helpers. Trends Immunol 2007;28(5):201-206.

(171) Stern-Ginossar N, Mandelboim O. Control LPS or get killed. Blood 2007;109(9):3614-3615.

(172) Gonen-Gross T, Mandelboim O. HLA-G Complexes Are Observed on the Cell Surface. Hum Immunol 2007;68(4):227-232.

(173) Yu Q, Chow EMC, Wong H, Gu J, Mandelboim O, Gray-Owen SD, et al. CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway. J Biol Chem 2006;281(51):39179-39193.

(174) Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, et al. Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol 2006;177(9):6062-6071.

(175) Arnon TI, Markel G, Mandelboim O. Tumor and viral recognition by natural killer cells receptors. Semin Cancer Biol 2006;16(5):348-358.

(176) Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006;12(9):1065-1074.

(177) Betser-Cohen G, Katz G, Gonen-Gross T, Stern N, Arnon TI, Achdout H, et al. Reduced KIR2DL1 recognition of MHC class I molecules presenting phosphorylated peptides. J Immunol 2006;176(11):6762-6769.

(178) Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, Achdout H, et al. Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 2006;7(5):517-523.

(179) Drukker M, Katchman H, Katz G, Friedman SE-, Shezen E, Hornstein E, et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 2006;24(2):221-229.

(180) Arnon TI, Achdout H, Levi O, Markel G, Saleh N, Katz G, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 2005;6(5):515-523.

(181) Hanna J, Mussaffi H, Steuer G, Hanna S, Deeb M, Blau H, et al. Functional aberrant expression of CCR2 receptor on chronically activated NK cells in patients with TAP-2 deficiency. Blood 2005;106(10):3465-3473.

(182) Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Hořejší V, et al. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and β2-microglobulin-free HLA-G molecules. J Immunol 2005;175(8):4866-4874.

(183) Azuz-Lieberman N, Markel G, Mizrahi S, Gazit R, Hanna J, Achdout H, et al. The involvement of NK cells in ankylosing spondylitis. Int Immunol 2005;17(7):837-845.

(184) Stern N, Markel G, Arnon TI, Gruda R, Wong H, Gray-Owen SD, et al. Carcinoembryonic antigen (CEA) inhibits NK killing via interaction with CEA-related cell adhesion molecule 1. J Immunol 2005;174(11):6692-6701.

(185) Yagel S, Goldman-Wohl DS, Mandelboim O, Hanna Y, Hochner-Celnikier D. Maternal adaptation to vasculogenesis and angiogenesis at the feto-maternal interface. Thromb Res 2005;115(SUPPL.):97-99.

(186) Munitz A, Bachelet I, Fraenkel S, Katz G, Mandelboim O, Simon H-, et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol 2005;174(1):110-118.

(187) Hanna J, Fitchett J, Rowe T, Daniels M, Heller M, Gonen-Gross T, et al. Proteomic analysis of human natural killer cells: Insights on new potential NK immune functions. Mol Immunol 2005;42(4 SPEC. ISS.):425-431.

(188) Hanna J, Bechtel P, Zhai Y, Youssef F, McLachlan K, Mandelboim O. Novel insights on human NK cells' immunological modalities revealed by gene expression profiling. J Immunol 2004;173(11):6547-6563.

(189) Markel G, Gruda R, Achdout H, Katz G, Nechama M, Blumberg RS, et al. The critical role of residues 43R and 44Q of carcinoembryonic antigen cell adhesion molecules-1 in the protection from killing by human NK cells. J Immunol 2004;173(6):3732-3739.

(190) Drukker M, Katz G, Mandelboim O, Benvenisty N. Immunogenicity of Human Embryonic Stem Cells. Handbook of Stem Cells; 2004. p. 663-674.

(191) Markel G, Achdout H, Katz G, Ling K-, Salio M, Gruda R, et al. Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. Eur J Immunol 2004;34(8):2138-2148.

(192) Katz G, Gazit R, Arnon TI, Gonen-Gross T, Tarcic G, Markel G, et al. MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 2004;173(3):1819-1825.

(193) Gazit R, Rechnitzer H, Achdout H, Katzenell A, Katz G, Markel G, et al. Recognition of Mycoplasma hyorhinis by CD99-Fc molecule. Eur J Immunol 2004;34(7):2032-2040.

(194) Weiss L, Reich S, Mandelboim O, Slavin S. Murine B-cell leukemia lymphoma (BCL1) cells as a target for NK cell-mediated immunotherapy. Bone Marrow Transplant 2004;33(11):1137-1141.

(195) Wald O, Pappo O, Safadi R, Dagan-Berger M, Beider K, Wald H, et al. Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus. Eur J Immunol 2004;34(4):1164-1174.

(196) Gazit R, Garty B-, Monselise Y, Hoffer V, Finkelstein Y, Markel G, et al. Expression of KIR2DL1 on the entire NK cell population: A possible novel immunodeficiency syndrome [1]. Blood 2004;103(5):1965-1966.

(197) Markel G, Mussaffi H, Ling K-, Salio M, Gadola S, Steuer G, et al. The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood 2004;103(5):1770-1778.

(198) Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, Katz G, et al. The mechanisms controlling the recognition of tumor- and virus-infected cells by NKp46. Blood 2004;103(2):664-672.

(199) Hanna J, Gonen-Gross T, Fitchett J, Rowe T, Daniels M, Arnon TI, et al. Novel APC-like properties of human NK cells directly regulate T cell activation. J Clin Invest 2004;114(11):1612-1623.

(200) Nachmias B, Ashhab Y, Bucholtz V, Drize O, Kadouri L, Lotem M, et al. Caspase-mediated cleavage converts livin from an antiapoptotic to a proapoptotic factor: Implications for drug-resistant melanoma. Cancer Res 2003;63(19):6340-6349.

(201) Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, et al. Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice. Blood 2003;102(6):1951-1958.

(202) Hanna J, Wald O, Goldman-Wohl D, Prus D, Markel G, Gazit R, et al. CXCL12 expression by invasive trophoblasts induces the specific migration of CD16- human natural killer cells. Blood 2003;102(5):1569-1577.

(203) Dong Y, Lieskovska J, Kedrin D, Porcelli S, Mandelboim O, Bushkin Y. Soluble nonclassical HLA generated by the metalloproteinase pathway. Hum Immunol 2003;64(8):802-810.

(204) Gonen-Gross T, Achdout H, Gazit R, Hanna J, Mizrahi S, Markel G, et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003;171(3):1343-1351.

(205) Achdout H, Arnon TI, Markel G, Gonen-Gross T, Katz G, Lieberman N, et al. Enhanced recognition of human NK receptors after influenza virus infection. J Immunol 2003;171(2):915-923.

(206) Gonen-Gross T, Gazit R, Achdout H, Hanna J, Mizrahi S, Markel G, et al. Special Organization of the HLA-G Protein on the Cell Surface. Hum Immunol 2003;64(11):1011-1016.

(207) Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A 2002;99(15):9864-9869.

(208) Vankayalapati R, Wizel B, Weis SE, Safi H, Lakey DL, Mandelboim O, et al. The NKp46 receptor contributes to NK cell lysis of mononuclear phagocytes infected with an intracellular bacterium. J Immunol 2002;168(7):3451-3457.

(209) Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol 2002;168(6):2803-2810.

(210) Tan P, Kropshofer H, Mandelboim O, Bulbuc N, Hämmerling GJ, Momburg F. Recruitment of MHC class I molecules by tapasin into the transporter associated with antigen processing-associated complex is essential for optimal peptide loading. J Immunol 2002;168(4):1950-1960.

(211) Markel G, Wolf D, Hanna J, Gazit R, Goldman-Wohl D, Lavy Y, et al. Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions. J Clin Invest 2002;110(7):943-953.

(212) Mandelboim O, Porgador A. NKp46. Int J Biochem Cell Biol 2001;33(12):1147-1150.

(213) Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, Mandelboim O. Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001;31(9):2680-2689.

(214) Katz G, Markel G, Mizrahi S, Arnon TI, Mandelboim O. Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 41. J Immunol 2001;166(12):7260-7267.

(215) Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, Bushkin Y, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 2001;409(6823):1055-1060.

(216) Lieberman N, Mandelboim O. The role of NK cells in innate immunity. Adv Exp Med Biol 2000;479:137-145.

(217) Baba E, Erskine R, Boyson JE, Cohen GB, Davis DM, Malik P, et al. N-linked carbohydrate on human leukocyte antigen-C and recognition by natural killer cell inhibitory receptors. Hum Immunol 2000;61(12):1202-1218.

(218) Davis DM, Chiu I, Fassett M, Cohen GB, Mandelboim O, Strominger JL. The human natural killer cell immune synapse. Proc Natl Acad Sci U S A 1999;96(26):15062-15067.

(219) Porgador A, Dorfman JR, Corral L, Strominger JL, Mandelboim O, Restifo NP. Tumor variability and sensitivity to T and NK cells: Implications for cancer immunotherapy. Gann Monogr Cancer Res 1999;48:105-115.

(220) Pazmany L, Mandelboim O, Vales-Gomez M, M. Davis D, C. Becker T, T. Reyburn H, et al. Human leucocyte antigen-G and its recognition by natural killer cells. J Reprod Immunol 1999;43(2):127-137.

(221) Mandelboim O, Malik P, Davis DM, Jo CH, Boyson JE, Strominger JL. Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proc Natl Acad Sci U S A 1999;96(10):5640-5644.

(222) Davis DM, Mandelboim O, Luque I, Baba E, Boyson J, Strominger JL. The transmembrane sequence of human histocompatibility leukocyte antigen (HLA)-C as a determinant in inhibition of a subset of natural killer cells. J Exp Med 1999;189(8):1265-1274.

(223) Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999;10(6):661-671.

(224) Mandelboim O, Kent S, Davis DM, Wilson SB, Okazaki T, Jackson R, et al. Natural killer activating receptors trigger interferon γ secretion from T cells and natural killer cells. Proc Natl Acad Sci U S A 1998;95(7):3798-3803.

(225) Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. Erratum: CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma (Nature (1994) 369 (67-71)). Nature 1998;392(6673):311.

(226) Eisenbach L, Mandelboim O, Bar-Haim E, Carmon L, Copcow H, El-Shami K, et al. Tumor-associated antigen peptides as anti-metastatic vaccines. Int J Pept Res Ther 1998;5(5-6):323-328.

(227) Eisenbach L, Mandelboim O, Bar-Haim E, Carmon L, Copcow H, El-Shami K, et al. Tumor-associated antigen peptides as anti-metastatic vaccines. Lett Pept Sci 1998;5(5-6):323-328.

(228) Mandelboim O, Pazmany L, Davis DM, Valés-Gómez M, Reyburn HT, Rybalov B, et al. Multiple receptors for HLA-G on human natural killer cells. Proc Natl Acad Sci U S A 1997;94(26):14666-14670.

(229) Mandelboim O, Bar-Haim E, Vadai E, Fridkin M, Eisenbach L. Identification of Shared Tumor-Associated Antigen Peptides between Two Spontaneous Lung Carcinomas. J Immunol 1997;159(12):6030-6036.

(230) Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. Erratum: CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma (Nature (1994) 369 (67-71)). Nature 1997;390(6660):643.

(231) Porgador A, Mandelboim O, Restifo NP, Strominger JL. Natural killer cell lines kill autologous β2-microglobulin-deficient melanoma cells: Implications for cancer immunotherapy. Proc Natl Acad Sci U S A 1997;94(24):13140-13145.

(232) Davis DM, Reyburn HT, Pazmany L, Chiu I, Mandelboim O, Strominger JL. Impaired spontaneous endocytosis of HLA-G. Eur J Immunol 1997;27(10):2714-2719.

(233) Mandelboim O, Wilson SB, Valés-Gómez M, Reyburn HT, Strominger JL. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci U S A 1997;94(9):4604-4609.

(234) Reyburn HT, Mandelboim O, Valés-Gómez M, Davis DM, Pazmany L, Strominger JL. The class I MHC homologue of human cytomegalovirus inhibits attack by natural killer cells. Nature 1997;386(6624):514-517.

(235) Mandelboim O, Reyburn HT, Sheu EG, Valés-Gómez M, Davis DM, Pazmany L, et al. The binding site of NK receptors on HLA-C molecules. Immunity 1997;6(3):341-350.

(236) Mandelboim O, Davis DM, Reyburn HT, Valés-Gómez M, Sheu EG, Pazmany L, et al. Enhancement of Class II-restricted T cell responses by costimulatory NK receptors for Class I MHC proteins. Science 1996;274(5295):2097-2100.

(237) Pazmany L, Mandelboim O, Valés-Gómez M, Davis DM, Reyburn HT, Strominger JL. Protection from natural killer cell-mediated lysis by HLA-G expression on target cells. Science 1996;274(5288):792-795.

(238) Mandelboim O, Reyburn HT, Valés-Gómez M, Pazmany L, Colonna M, Borsellino G, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996;184(3):913-922.

(239) Mandelboim O, Vadai E, Feldman M, Eisenbach L. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Ther 1995;2(10):757-765.

(240) Mandelboim O, Vadai E, Fridkin M, Katz-Hillel A, Feldman M, Berke G, et al. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nat Med 1995;1(11):1179-1183.

(241) Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994;369(6475):67-71.

(242) Mandelboim O, Feldman M, Eisenbach L. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients: Implications for the T cell repertoire. J Immunol 1992;148(11):3666-3673.